Publications on Special Topics About NCI-MATCH
Listed by chronology
Journal Topic Title and Citation Lead & Corresponding Authors
Seminars in Oncology Overview Molecular Analysis for Therapy Choice: NCI MATCH
Conley BA. Semin Oncol. 2014 Jun;41(3):297-9
 Barbara A. Conley
James H. Doroshow
Chinese Clinical Oncology Overview An overview of the NCI Precision Medicine trials-NCI MATCH and MPACT
Do K. Chin Clin Oncol. 2015 Sep;4(3):31
 Khanh Do
Alice P. Chen
Journal of Molecular Diagnostics
 Next-Gen Sequencing Assay
 Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial
Molecular Analysis for Therapy Choice Clinical Trial
Lih CJ. J Mol Diagn. 2017 Mar;19(2):313–327
 Chih-Jian Lih
P. Mickey Williams
Current Problems in Cancer Next-Gen Sequencing Assay Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience
Lih CJ. Curr Probl Cancer. 2017 May-Jun;41(3):201-211		 Chih-Jian Lih
Naoko Takebe
Current Problems in Cancer Defining Precision Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH
O’Sullivan Coyne G. Curr Probl Cancer. 2017 May-Jun;41(3):182-193		 Geraldine O’Sullivan Coyne
Alice P. Chen
Clinical Cancer Research Immunohisto-chemical Assays Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial
Koury JD. Clin Cancer Res. 2018 Feb 1;24(3):521–531		 Joseph D. Khoury
Journal of the National Cancer Institute
 Implementation The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Flaherty KT. J Natl Cancer Ins. 2020 Jan 10;pii:djz245
 Keith T. Flaherty
Peter J. O’Dwyer
JCO Precision Oncology Physician Survey Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial
Chen AP, JCO Precision Oncology no 4 (Oct 5, 2020) 1207-1216		 Alice P. Chen
Journal of Clinical Oncology Central Screening Cohort Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Flaherty KT, J Clin Oncol. 2020 Oct 13: JCO.19.03010		 Keith T. Flaherty

 

Final Results for NCI-MATCH Treatment Arms
Listed by chronology
Journal Arm Title and Citation Lead Author
Annals of Oncology Q Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Subprotocol Q
Jhaveri KL. Ann Oncol. 2019 Nov 1;30(11):1821-1830		 Komal L. Jhaveri
Journal of Clinical Oncology Z1D Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study
Azad NS. J Clin Oncol. 2019 Nov 25:JCO.1900818
 Nilofer S. Azad
Clinical Cancer Research R Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: Results from NCI-MATCH (EAY131)
Johnson DB. Clin Cancer Res. 2020 Jan 10		 Douglas B. Johnson
Journal of Clinical Oncology W Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Chae YK. J Clin Oncol. 2020 May 28:JCO.19.02630		  Young K. Chae
Journal of Clinical Oncology H Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
Salama AKS. J Clin Oncol. 2020 Aug 06:JCO.20.00762		 April K.S. Salama
JAMA Oncology Y Effect of Capivasertib in Patients with an AKT1 E17K-mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
Kalinsky KM. JAMA Oncol. 2020 Dec 30		 Kevin M. Kalinsky
Clinical Cancer Research Z1A Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors
Cleary JM. Clin Cancer Res. 2021 Feb 26
 James M. Cleary

 

Return to Top | Return to NCI-MATCH / EAY131 Home Page